← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 25.4% to $40.5M, while Net income increased 32.5% to ($160.1M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $40.5MWatch
- Profitability — Net income ($160.1M)Watch
- Cash generation — Free cash flow ($165.8M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 9 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Editas Medicine, Inc.: This Annual Report on Form 10-K includes statistical and other industry and market data, which we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys, and studies conducted by third parties.
Where the revenue comes from
Fiscal 2025, as Editas Medicine, Inc. reports it. History and quarterly detail are in the app.
Leadership changes
From Editas Medicine, Inc.'s own filings, the day they're filed.
- Amy Parison · Chief Financial Officer · departureeff. 2025-03-28
- Erick Lucera · Chief Financial Officer · departureeff. 2025-03-28
- Akshay Vaishnaw · Directors · departureeff. 2024-06-30
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-05-26
- 8-K · Company announcement2026-05-26
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Editas Medicine, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.